CONNECTA Therapeutics Initiates Phase IIa Clinical Trial of CTH120, a First-in-Class Neuroplasticity Modulator, in Fragile X Syndrome
- Builds on positive Phase I safety data and represents a key value-inflection milestone for the Company
- Advances a potentially disease-modifying approach for fragile X syndrome, a condition with no approved targeted therapies
Barcelona, Spain – 10 June 2026 – CONNECTA Therapeutics, a clinical-stage biotech company pioneering first-in-class neuroplasticity modulators to address unmet medical needs in central nervous system (CNS) disorders, today announced the initiation of its Phase IIa clinical trial evaluating its lead first-in-class program, CTH120, in adult males with fragile X syndrome (FXS).
